Endocrine disorders in Fanconi anemia: recommendations for screening and treatment.

S P E C I A L

F E A T U R E R e v i e w

Endocrine Disorders in Fanconi Anemia: Recommendations for Screening and Treatment Anna Petryk, Roopa Kanakatti Shankar, Neelam Giri, Anthony N. Hollenberg, Meilan M. Rutter, Brandon Nathan, Maya Lodish, Blanche P. Alter, Constantine A. Stratakis, and Susan R. Rose Division of Pediatric Endocrinology (A.P., B.N.), University of Minnesota Masonic Children’s Hospital, Minneapolis, Minnesota 55454; Department of Pediatrics (R.K.S.), Children’s Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia 23229; Clinical Genetics Branch (N.G., B.P.A.), Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20850; Division of Endocrinology, Diabetes and Metabolism (A.N.H.), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; Division of Endocrinology (M.M.R., S.R.R.), Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229; Pediatric Endocrinology Inter-Institute Training Program (M.L.), National Institutes of Health, Bethesda, Maryland 20892; and Section on Endocrinology and Genetics (M.L., C.A.S.), Program on Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland 20892

Context: Endocrine problems are common in patients with Fanconi anemia (FA). About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility. The goal of this report is to provide an overview of endocrine abnormalities and guidelines for routine screening and treatment to allow early diagnosis and timely intervention. Evidence Acquisition: This work is based on a comprehensive literature review, including relevant articles published between 1971 and 2014, and proceedings of a Consensus Conference held by the Fanconi Anemia Research Fund in 2013. Evidence Synthesis: The panel of experts collected published evidence and discussed its relevance to reflect current information about the endocrine care of children and adults with FA before the Consensus Conference and through subsequent deliberations that led to the consensus. Conclusions: Individuals with FA should be routinely screened for endocrine abnormalities, including evaluation of growth; glucose, insulin, and lipid metabolism; thyroid function; puberty; gonadal function; and bone mineral metabolism. Inclusion of an endocrinologist as part of the multidisciplinary patient care team is key to providing comprehensive care for patients with FA. (J Clin Endocrinol Metab 100: 803– 811, 2015)

anconi anemia (FA) is a congenital syndrome associated with anomalies of hands/thumbs/radii, heart, kidneys, trachea, and ears and caused by mutations in the genetic complex required for repair of DNA breakage (1). Most FA patients develop bone marrow failure during childhood, requiring hematopoietic cell

F

transplantation (HCT). In addition, patients with FA have a lifelong risk for cancer. Both FA and its treatment can affect the endocrine system. Patients with FA are usually shorter than the general population and do not achieve their target heights. Short stature may be due to reduced GH secretion, hypothy-

ISSN Print 0021-972X ISSN Online 1945-7197 Printed in U.S.A. Copyright © 2015 by the Endocrine Society Received December 10, 2014. Accepted January 6, 2015. First Published Online January 9, 2015

Abbreviations: BA, bone age; BMD, bone mineral density; BMI, body mass index; DXA, dual-energy x-ray absorptiometry; FA, Fanconi anemia; GHD, GH deficiency; HCT, hematopoietic cell transplantation; IGFBP3, IGF-binding protein 3; MRI, magnetic resonance imaging; OGTT, oral glucose tolerance test; PSIS, pituitary stalk interruption syndrome; SGA, small for gestational age.

doi: 10.1210/jc.2014-4357

J Clin Endocrinol Metab, March 2015, 100(3):803– 811

jcem.endojournals.org

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 09 April 2015. at 13:29 For personal use only. No other uses without permission. . All rights reserved.

803

804

Petryk et al

Endocrine Guidelines in FA

roidism, or abnormal glucose homeostasis with deficient pancreatic ␤-cell insulin secretion and/or insulin resistance. Puberty, gonadal function, and fertility may be abnormal. Children with FA usually have bone mineral density (BMD) Z-scores within the expected range for age when adjusted for short stature, but lower than average. Adults with FA have been reported to have osteopenia or osteoporosis. The goal of this report is to provide an overview of endocrine abnormalities and guidelines for routine screening and treatment to allow early diagnosis and timely intervention.

Short Stature About 60% of FA patients are shorter than the reference population, with average height SD of ⫺2.2 for children and ⫺2.0 for adults (corresponding to about 150 cm in women and 161 cm in men) (2– 4). However, some individuals with FA have normal height, and 10% have height even above average compared to the general population (2). Etiology of short stature in FA is multifactorial, including endocrine and nonendocrine causes. FA patients with hormone deficiencies (GH deficiency [GHD], hypothyroidism, or hypogonadism) are shorter (average height SD, ⫺2.2) than those with normal hormone production (average height SD, ⫺1.0) (2, 4). However, short stature in FA cannot be explained by endocrine deficiencies alone. Even FA individuals without endocrinopathies tend to be short, with about half being below normal. Thus, hormonal replacement therapy may not always normalize growth. Certain FA mutations associate with short stature. For example, patients with the IVS4 mutation of FANCC have average height SD of ⫺4.3 (4). Average birth weight in FA is ⫺1.8 SD, with half of FA children born small for gestational age (SGA) (2). In general, 90% of SGA children catch up to normal height. In contrast, in FA only 25% of SGA children catch up to normal height (2). Median height SD in FA SGA is ⫺2.6, compared to ⫺2.0 after appropriate for gestational age birth (2). Medications used in FA such as androgens (to promote red cell generation) may affect growth and bone maturation and impair adult height (5, 6). Although low-dose androgens used in constitutional delay improve growth, androgens have the potential to accelerate epiphyseal maturation, mediated by aromatization of T to estrogen (7, 8). Some medications (eg, corticosteroids to suppress graft-vs-host disease) or radiation therapy used during HCT may affect thyroid or gonadal function and impact longitudinal growth. In addition, total body irradiation used in preparation for HCT directly impacts spinal growth potential (9).


Screening for growth failure Growth should be closely monitored in FA children, and nutritional/medical causes for poor growth should be identified early. Children with height SD ⱕ⫺2.0 or a decline in growth velocity should have assessment of GH and thyroid hormone secretion, pubertal status, and a bone age (BA) radiograph (Table 1). Adult height prediction using BA may overestimate height in FA because the algorithm assumes continued healthy growth, optimal nutrition, normal hormone secretion, and normal timing of puberty, assumptions not necessarily correct in FA. Androgen therapy accelerates BA, whereas hypothyroidism, GHD, hypogonadism, and corticosteroid therapy delay BA. Although midparental height can predict adult height of healthy children, this prediction is usually not helpful in FA. Despite parents’ heights being similar to the general population (2), FA children are shorter than average, suggesting that growth impairment is an inherent feature of FA. Recommendations for treatment Treatment of growth failure or short stature requires identification of underlying causes. Specific hormone therapy is discussed below.

GH Deficiency Case reports have described GHD in FA (10 –14). FA children show reduced overnight spontaneous (4) and stimulated GH secretion, with 54% failing the GH stimulation test after clonidine and 72% after arginine (4). Peak GH response to stimulation is also delayed. Using more stringent criteria for GHD (GH peak ⱕ 5 ␮g/L) and without sex steroid priming, 12% tested as GH deficient (2). GHD was more common after HCT compared to those without HCT (25 vs 8%) (2). Thus, results suggest that some FA children have classical GHD, whereas others may have hypothalamic dysfunction leading to “partial” GHD. Screening for GHD Screening for GHD in a short child with slow growth includes measurement of IGF-1 and IGF-binding protein 3 (IGFBP3) (Table 1). If IGF-1 and IGFBP3 are ⬍⫺1 SD for age, evaluation should include standard GH stimulation testing (15). IGF-1 is known to be a poor marker of GHD in undernutrition or after total body irradiation or cranial radiation. Sex steroid priming should be considered before GH stimulation testing in prepubertal girls ⱖ10 years of age or in prepubertal boys ⱖ11 years of age (16, 17). GH stimulation tests include clonidine and arginine, or glucagon (17–19). GH peak is considered normal if it is ⬎10 ng/mL (20). FA patients with GHD should


doi: 10.1210/jc.2014-4357

Table 1.


805

Endocrine Screening in FA Annual Screening for All

Detailed Testing in Some Patients

Growth

Height, weight, review of growth chart, BMI monitoring, assess Tanner stage, and nutritional intake

Glucose, insulin, and lipid metabolism

Home glucometer testing with pre-meal and 2-h post-meal glucose levels, HbA1c (after HCT), fasting lipid profile (after age 10 y), blood pressure Height, weight, early morning TSH, FT4

For growth failure: 䡠 IGF-1, IGFBP3 䡠 BA radiograph 䡠 FT4, TSH For suspected GHD: 䡠 GH stimulation tests 䡠 Pituitary MRI if there is evidence of any pituitary hormone deficiency If patient is overweight/obese or hyperlipidemic: 2-h OGTT If patient had previous abnormal OGTT but is not diabetic: repeat OGTT yearly For suspected central hypothyroidism: determine ratio of 8 AM TSH to afternoon TSH If there is evidence of other pituitary hormone deficiency or pituitary abnormality on MRI: administer low-dose ACTH stimulation test If there is early/delayed puberty or suspected hypogonadism: 䡠 BA radiograph 䡠 LH, FSH, E2, and AMH (females), T and inhibin-B (males) Consider DXA scan for BMD: 䡠 Every 5 y starting at age 14 y if no prior HCT 䡠 Before HCT and 1 y after HCT 䡠 Repeat in 1 y if low BMD 䡠 Every 2 y if hypogonadism or premature ovarian failure

Thyroid Cortisol

Puberty and gonadal function

Pubertal staging; assess menstrual history and clinical evidence for hypogonadism (after usual age of start of puberty)

Bone mineral metabolism

25OHD level; assess dietary calcium and vitamin D intake

Abbreviations: AMH, anti-Müllerian hormone; FT4, free T4; 25OHD, 25-hydroxyvitamin D; HbA1c, glycosylated hemoglobin.

undergo pituitary magnetic resonance imaging (MRI) scan and evaluation for central hypothyroidism and ACTH deficiency. Safety and efficacy of GH One study has described the efficacy of GH treatment in four FA children with GHD after HCT (21). Mean age at FA diagnosis was 7.0 ⫾ 1.9 years, at HCT was 8.7 ⫾ 2.2 years, and at the start of GH treatment was 10.7 ⫾ 1.8 years. GH dose was 0.28 ⫾ 0.03 mg/kg/wk, and duration of treatment was 2.4 – 6.6 years. GH treatment was well tolerated and resulted in an increase in height SD of at least 0.5 in 75% of patients. Mean increase in height SD was 0.9 ⫾ 0.6, with no adverse events. The long-term risk of GH treatment in FA patients is unknown; therefore, continued surveillance is needed. FA patients are inherently at increased risk of malignancy, including acute leukemia (particularly before HCT), head/ neck cancers, and genitourinary cancer (22–24). Although HCT reduces the risk for leukemia, FA patients have increased risk for solid tumors. No data suggest that cancer risk is further increased in FA patients treated with GH. GH registries have provided useful safety and efficacy data on the use of GH in the general population and in cancer

survivors, but they include few subjects with FA (25–31). In a large longitudinal study of over 12 000 cancer survivors, including 330 treated with GH, there was no increased risk of cancer recurrence with GH (31–33). The risk for a second neoplasm (mostly solid tumors) was slightly increased in survivors treated with GH, although the relative risk was declining with follow-up (33). Other studies have shown no increased risk of cancer recurrence (34 –36). Some found no increase in second neoplasias (36, 37), whereas others found continuing concern (34, 35, 38). A few studies raised concerns about vascular health, including heart disease and stroke (39 – 41), particularly with higher GH dosing. Other studies have suggested no association of GH therapy with stroke risk (36, 42– 45). Recommendations for treatment GHD is treated with recombinant human GH according to published guidelines (46). Physicians should counsel FA families as to the risks and benefits of therapy. A short child with FA can be treated with GH if GHD has been convincingly documented (short stature, slow growth rate, and low stimulated GH peak). GH treatment in the absence of GHD is controversial in FA, with no consensus on safety of GH therapy in FA patients. However, severe


806

Petryk et al


short stature may have a negative impact on quality of life and daily functioning. In the absence of long-term safety data in the FA population, GH therapy in FA patients should be titrated to achieve IGF-1 concentrations in the mid-normal range for age (between 0 and 1 SD). Therapy should be discontinued immediately if routine hematological examination reveals clonal hematopoietic stem cell proliferation. GH therapy should also be temporarily discontinued before HCT and for at least 6 months afterward, as well as during critical illness (47).

Undernutrition and Low Body Mass Index (BMI) BMI is normal in about half of FA patients but may range from low to high (2– 4). Median BMI SD is ⫺0.2 in children (⫺3.3 to ⫹5.0 in males; ⫺2.6 to ⫹6.0 in females), and ⫺1.0 in adults (⫺2.8 to ⫹2.0 in males; ⫺2.7 to ⫹3.2 in females) (2). About 22–38% of FA patients have low BMI (2, 3). Although low BMI correlates with short stature (2), height SD is affected to a much greater degree, indicating that undernutrition is not sufficient to account for the short stature in FA (2, 4). Factors contributing to poor weight gain include increased caloric requirements, decreased intake due to chronic illness or gastrointestinal causes, and insulin deficiency/hyperglycemia (48). SGA is associated with a nonsignificant trend of lower median BMI SD compared to those born appropriate for gestational age (⫺1.3 vs ⫺0.5; P ⫽ .09) (2). There is no apparent relationship of HCT status or complementation group with low BMI (2). Screening for undernutrition and low BMI Growth, including height, weight, and BMI, should be measured and plotted on a growth chart at least annually (Table 1). Nutritional intake and gastrointestinal causes should be assessed. Recommendations for treatment Regular nutritional assessment and counseling are recommended to maintain normal weight and BMI, optimize growth and bone health, and reduce the risk for impaired glucose tolerance, diabetes, and metabolic syndrome. Any underlying medical cause should be treated.

Abnormal Glucose or Insulin Metabolism FA patients are at greater risk for diabetes mellitus than the general population (49). The prevalence of diabetes is approximately 8 –10% in FA patients, whereas an additional 27– 68% may have impaired glucose tolerance (2– 4, 48,


50). Diabetes can occur either before or after HCT and has not been associated with an individual FA genotype. The tendency toward hyperglycemia stems from both an impairment in ␤-cell function and insulin resistance. The insulinogenic index, a surrogate for ␤-cell secretion during the oral glucose tolerance test (OGTT), is significantly lower among FA patients compared to the control population (48). About 25% of post-HCT FA patients have reduced first-phase insulin release on the iv glucose tolerance test (50). Surrogates of increased insulin resistance (eg, homeostasis model of assessment for insulin resistance; elevated insulin levels) have been demonstrated in some FA cohorts (3, 4). There is also a tendency toward both higher insulin secretion (50) and hyperglycemia (3) in FA patients who are overweight or obese. These data support the contribution of both ␤-cell dysfunction with impairment of first-phase insulin secretion and insulin resistance (particularly in overweight patients) to the development of diabetes. The cause of impaired insulin secretion/action in FA patients is unknown but may be related to ␤-cell damage due to increased reactive oxygen species generation (51), or iron overload in heavily transfused patients, or medications used in FA treatment (androgens, corticosteroids) (4, 52–54). Guidelines regarding glucocorticoid use in FA should be the same as in any other subject; ie, use the minimum necessary. Screening for abnormal glucose and insulin metabolism All FA patients should be tested for abnormalities of glucose and insulin homeostasis upon diagnosis. Thereafter, annual screening may be considered (Table 1). Because impaired fasting glucose is not typical in FA, screening solely with a fasting sample may fail to identify patients with impaired glucose tolerance. Likewise, fasting or random insulin measurements should not be performed to make a diagnosis of hyperinsulinemia or insulin resistance. Screening of glucose tolerance can be initially performed by home glucometer testing with pre-meal and 2-hour post-meal glucose levels. In those with suspected abnormalities and risk factors (overweight/obesity, hyperlipidemia), a more detailed evaluation should consist of a 2-hour OGTT, with samples for both glucose and insulin obtained every 30 minutes (48). Insulin levels provide a useful adjunctive data source during an OGTT but have not been demonstrated to effectively predict progression to disease. An abnormal OGTT should be reassessed to monitor for progression to frank diabetes. Glycosylated hemoglobin and fructosamine levels may be deceptively normal due to impaired glycosylation or elevated levels of fetal hemoglobin in those with bone marrow failure (2) and are therefore not helpful in FA patients before HCT.


doi: 10.1210/jc.2014-4357

Recommendations for treatment All patients diagnosed with FA, regardless of OGTT results, should be placed on a healthy diet that avoids excessive intake of concentrated sweets but also provides adequate caloric, protein, calcium, and vitamin D intake. FA patients with diabetes should be treated with insulin or oral medications tailored to the cause of diabetes as in the general population. Administration of short-acting insulin with meals may be more beneficial than metformin, due to the abnormal pattern of insulin release in FA. Treatment with short-acting insulin at mealtime should be considered if postprandial glucose is consistently ⬎180 mg/dL or in patients with impaired glucose tolerance and poor weight gain where chronic hyperglycemia may be contributing. Whether FA patients with normal fasting glucose but impaired glucose tolerance should be treated with insulin is less clear. During HCT, many children with FA require both short-acting and long-acting insulin therapy for steroid-induced hyperglycemia. Metformin may be considered in overweight individuals, accompanied by increased surveillance because there are no long-term data on the risks or benefits of metformin in FA.

Dyslipidemia and Obesity Of 29 patients with FA that had lipid studies reported, 55% had dyslipidemia (elevated low-density lipoprotein in 21%, low high-density lipoprotein in 31%, and elevated triglycerides in 10%) (3). Dyslipidemia was associated with glucose intolerance and was observed in 40% of patients with hyperglycemia or insulin resistance. In a later report, 17% of pediatric and adult FA patients had hypercholesterolemia (2). Metabolic syndrome (defined as overweight/obesity, dyslipidemia, and insulin resistance) was diagnosed in 21% of adults with FA, whereas 50% of children tested had at least one metabolic abnormality (3). In these studies, the impact of HCT on dyslipidemia was not clear. Thus, FA patients are at increased risk for components of the metabolic syndrome independent of transplant status. The risk for cardiovascular disease in this population is currently unknown. Screening for metabolic abnormalities Fasting lipid profile should be considered on an annual basis in patients ⬎10 years of age (Table 1). Screening should also include blood pressure measurement. Recommendations for treatment A healthy diet and exercise regimen must be optimized and emphasized.


807

Hypothyroidism Many children with FA have mildly abnormal serum thyroid hormone levels, such as borderline low free T4 or borderline elevated TSH (2– 4, 55, 56). About 60% of individuals with FA have primary hypothyroidism. The mechanism of hypothyroidism in FA is uncertain, but it is usually not autoimmune in nature. It has been speculated that unrepaired DNA damage from oxidative injury may lead to thyroid cell apoptosis. Central hypothyroidism is thought to be due to hypothalamic dysfunction. Screening for hypothyroidism Thyroid function should be evaluated annually (or more frequently if clinically indicated) by obtaining early morning free T4 and TSH levels (Table 1). Subclinical hypothyroidism may manifest as only TSH elevation without reduced free T4 level. Central hypothyroidism is suggested by a low free T4 and a normal (or low) TSH, or by a low-normal free T4 with a TSH value that is not significantly higher at 8 AM than it is later in the day (56). Individuals with central hypothyroidism should be evaluated for other pituitary hormone deficiencies and have a pituitary MRI. Although thyroid hormone binding may be reduced in FA patients, particularly during androgen therapy (4), it is not clinically significant. Recommendations for treatment Hypothyroidism should be treated promptly. Using a TSH cutoff ⬎3 mU/L as a threshold for treatment of subclinical hypothyroidism may offer growth benefit for FA children (55, 57), although it remains controversial. Therapeutic target TSH in primary hypothyroidism should be ⬍3 mU/L. In central hypothyroidism, therapeutic target should be a free T4 just above the middle of the normal range.

Pituitary Abnormalities FA children tend to have smaller pituitary size than the reference population (58). The reported midline brain defects include absent corpus callosum, absent septum pellucidum, septo-optic dysplasia, and pituitary stalk interruption syndrome (PSIS) (3, 14, 21, 59 – 61). PSIS may be associated with permanent GHD and severe growth failure (mean height SD, ⫺4.6; range, ⫺3.7 to ⫺5.7). In addition, these patients are at risk for multiple pituitary hormone deficiencies, including central hypothyroidism and hypogonadotropic hypogonadism. Hypothalamic dysfunction has been reported even in the absence of a detectible midline central nervous system defect (11, 58). Cryptorchidism and microphallus are common in males


808

Petryk et al


with PSIS (59). An ectopic pituitary gland has been reported in a patient with FA and GHD (21). Screening for pituitary hormone deficiencies/abnormalities Evaluation should include assessment of GH secretion, gonadal and thyroid function, and cortisol sufficiency (Table 1). Although most FA patients have normal circadian cortisol levels and normal responses to ACTH administration (using 0.15 ␮g/kg of cosyntropin) (3), a lowdose (1 ␮g) ACTH stimulation test should be performed to evaluate for ACTH insufficiency if other pituitary hormone deficiencies or a pituitary abnormality on MRI are present. Serial endocrine testing is necessary in those with PSIS because pituitary hormone deficiencies may evolve over time. Recommended treatment Appropriate treatment should be instituted in patients diagnosed with any of the pituitary hormone deficiencies as described in the corresponding sections.

Puberty, Hypogonadism, and Fertility Children with FA may have early onset of puberty. More commonly, however, they enter puberty late. Delayed puberty in FA may be due to hypothalamic-pituitary dysregulation manifesting as blunted and/or prolonged LH responses to stimulation. Chronic illness and conditioning regimen used for HCT including radiation and chemotherapy may also affect gonadal function (59). Developmental anomalies of the genital tract are more frequent in FA patients than in the general population. Boys may have cryptorchidism, hypospadias, and small testes for age and pubertal status, reflecting reduced Sertoli cell mass and spermatogenesis. Girls with FA may have a unicornuate uterus or hemi-uteri (62). Adult FA patients have a high incidence of hypogonadism. Hypogenitalism with small testes and phallus is common in men with FA (up to 64%), whereas premature ovarian failure is common in females (up to 77%) (2, 3). Both hypergonadotropic (61) and hypogonadotropic hypogonadism (60) have been reported in FA. Fertility in FA patients is often impaired, with males often being infertile and females often having premature menopause and a significantly abbreviated window of fertility, although rare cases of fertility have been documented (62, 63). Contraception should always be considered when pregnancy is not desired. Infertility in men with FA is at least in part due to a reduced sperm count. GnRH has been shown to acutely up-regulate the expression of the FANCA mRNA and protein, suggesting that FANCA


may play a regulatory role in gonadal function (64). Disruption of FANCA in mice is associated with a reduction in fertility and hypogonadism (65). Animal studies have also shown that the FANCC protein is required for the proliferation of primordial germ cells (66). Screening for gonadal and pubertal disorders Onset, pubertal stage, and tempo of pubertal progression should be monitored by annual physical examination (Table 1). BA assessment can be useful in adolescents with delayed or abnormal progression of puberty, whereas hormone concentrations (LH, FSH, estradiol, or T) can be useful in adolescents and in adults with symptoms of hypogonadism. Anti-Müllerian hormone tends to be low in women with FA (67); persistent low levels can be used clinically as a marker of primary ovarian insufficiency and reduced ovarian reserve. Inhibin B, which negatively correlates with FSH, can be a useful marker of Sertoli cell function in males (68). Recommendations for treatment In the child with FA with precocious puberty and short stature, GnRH agonist therapy can delay puberty to achieve an average of a 4- to 5-cm increase in adult height over 4 years of therapy (69). In boys with no signs of puberty by age 14 years, low-dose T therapy can be initiated and gradually titrated up over several years to adult replacement levels. In girls with no signs of puberty by age 13 years, low-dose estrogen therapy may be started and slowly titrated to adult dose. Estrogen therapy increases bone mineralization, optimizes growth rate, and induces breast development. Medroxyprogesterone should be added when breakthrough bleeding occurs or after 2 years of estrogen replacement. BA should be monitored during T and estrogen therapy. In FA, there is no medical contraindication to the use of oral contraceptive pills.

Bone Mineral Density BMD in FA has been reported in a few studies, with differing conclusions. Osteopenia or osteoporosis has been reported in 12 of 13 adults with FA, although only two had undergone prior HCT, suggesting that some of the BMD deficits may exist before HCT (3). A more recent study also found that almost one-third of FA adults had a low BMD Z-score (⬍⫺2 SD), which correlated with hypogonadism but not with short stature (Kanakatti Shankar R, Giri N, Lodish MB, Reynolds JC, Sinaii N, Savage SA, Stratakis CA, Alter BP, unpublished data). In contrast, in 34 children and three adults with FA (including about equal numbers with prior HCT and no HCT), lumbar spine BMD Z-scores adjusted for height age were in the


doi: 10.1210/jc.2014-4357

normal range (70). Although BMD remained within normal limits, mean height-adjusted lumbar BMD Z-score was lower in patients who had undergone prior HCT (⫺0.9) compared with those who had not had prior HCT (⫺0.3) (70). Recent data suggest that total body BMD Z-score, but not lumbar spine BMD Z-score, is reduced in children with FA compared to healthy controls by about 0.8 SD, even after adjustment for short stature (71). We recommend that the BMD in children with FA be adjusted for height and Z-scores be calculated (72). There are limited data regarding whether BMD Z-scores in adults with FA should be adjusted for height. BMD may decrease after HCT, particularly during the first 6 months due to a decrease in bone formation and an increase in bone resorption (73, 74). Medications used during HCT (eg, glucocorticoids), hypogonadism, and GHD may all contribute to low BMD. Screening for bone health Yearly evaluation includes assessment of dietary calcium and vitamin D intake and measurement of serum 25-hydroxyvitamin D level (75). Dual-energy x-ray absorptiometry (DXA) evaluation of BMD is recommended before HCT and 1 year after HCT. DXA evaluation may begin at about age 14 years if there has been no HCT previously, with follow-up scans every 5 years or as dictated by risk factors (Table 1). Recommendations for treatment It is important to maintain adequate dietary intake of calcium and vitamin D. Supplementation should meet the recommended dietary allowance (76). The therapeutic target for vitamin D levels is 30 –70 ng/mL (77). Treatment of hypogonadism and GHD is beneficial for bone mineralization. Bisphosphonates are effective in preventing bone loss after HCT in adults (78, 79), but more data are needed before a routine recommendation to treat low BMD in FA children undergoing HCT (80). Treatment with bisphosphonates may be considered (after addressing vitamin D deficiency) in a child with FA who has a heightadjusted BMD Z-score ⬍⫺2.0 and has sustained clinically significant fractures defined as those that include a long bone fracture of the lower extremities, vertebral compression fracture, or two or more long bone fractures of the upper extremities (81, 82). Fracture risk in FA and the correlation with BMD measures is currently unknown. The risk/benefit ratio (83) must be evaluated by specialists before treatment because the safety profile in this patient population is currently unknown.

Acknowledgments Address all correspondence and requests for reprints to: Dr Anna Petryk, University of Minnesota, Masonic Children’s Hospital,


809

East Building Room MB671, 2450 Riverside Avenue, Minneapolis, MN 55454. E-mail: [email protected]. Or Dr Susan Rose, 3333 Burnet Avenue, MLC 7012, Cincinnati, OH 45242. E-mail: [email protected]. This work was supported in part by the National Institutes of Health (Grant R01 CA181024, to A.P.), the Intramural Research Program of the National Institute of Child Health and Human Development (to R.K.S., M.L., and C.A.S.), the Intramural Program of the National Institutes of Health, and the National Cancer Institute (to B.P.A. and N.G.). The Fanconi Anemia Research Fund supported costs associated with the 2013 Consensus Conference. Disclosure Summary: A.P., R.K.S., N.G., M.M.R., B.N., M.L., B.P.A., C.A.S., and S.R.R. have nothing to disclose. A.N.H. serves on data monitoring safety committees for Amgen.

References 1. Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res. 2009; 668:4 –10. 2. Rose SR, Myers KC, Rutter MM, et al. Endocrine phenotype of children and adults with Fanconi anemia. Pediatr Blood Cancer. 2012;59:690 – 696. 3. Giri N, Batista DL, Alter BP, Stratakis CA. Endocrine abnormalities in patients with Fanconi anemia. J Clin Endocrinol Metab. 2007; 92:2624 –2631. 4. Wajnrajch MP, Gertner JM, Huma Z, et al. Evaluation of growth and hormonal status in patients referred to the International Fanconi Anemia Registry. Pediatrics. 2001;107:744 –754. 5. Lindberg MK, Vandenput L, Movèrare Skrtic S, et al. Androgens and the skeleton. Minerva Endocrinol. 2005;30:15–25. 6. Allen DB. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am. 1996;25:699 –717. 7. Keenan BS, Richards GE, Ponder SW, Dallas JS, Nagamani M, Smith ER. Androgen-stimulated pubertal growth: the effects of testosterone and dihydrotestosterone on growth hormone and insulinlike growth factor-I in the treatment of short stature and delayed puberty. J Clin Endocrinol Metab. 1993;76:996 –1001. 8. Allen DB, Cuttler L. Clinical practice. Short stature in childhood– challenges and choices. N Engl J Med. 2013;368:1220 –1228. 9. Ranke MB, Schwarze CP, Dopfer R, et al. Late effects after stem cell transplantation (SCT) in children– growth and hormones. Bone Marrow Transplant. 2005;35(suppl 1):S77–S81. 10. Pochedly C, Collipp PJ, Wolman SR, Suwansirikul S, Rezvani I. Fanconi’s anemia with growth hormone deficiency. J Pediatr. 1971; 79:93–96. 11. Aynsley-Green A, Zachmann M, Werder EA, Illig R, Prader A. Endocrine studies in Fanconi’s anaemia. Report of 4 cases. Arch Dis Child. 1978;53:126 –131. 12. Zachmann M, Illig R, Prader A. Fanconi’s anemia with isolated growth hormone deficiency. J Pediatr. 1972;80:159 –160. 13. Nordan UZ, Humbert JR, MacGillivray MH, Fitzpatrick JE. Fanconi’s anemia with growth hormone deficiency. Am J Dis Child. 1979;133:291–293. 14. Dupuis-Girod S, Gluckman E, Souberbielle JC, Brauner R. Growth hormone deficiency caused by pituitary stalk interruption in Fanconi’s anemia. J Pediatr. 2001;138:129 –133. 15. Nunez SB, Municchi G, Barnes KM, Rose SR. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 concentrations compared to stimulated and night growth hormone in the evaluation of short children–a clinical research center study. J Clin Endocrinol Metab. 1996;81:1927–1932. 16. Marin G, Domené HM, Barnes KM, Blackwell BJ, Cassorla FG,


810

17.

18.

19.

20.

21.

22. 23.

24.

25.

26.

27.

28.

29.

30. 31.

32.

33.

34.

35.

Petryk et al


Cutler GB Jr. The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J Clin Endocrinol Metab. 1994;79:537–541. Martínez AS, Domené HM, Ropelato MG, et al. Estrogen priming effect on growth hormone (GH) provocative test: a useful tool for the diagnosis of GH deficiency. J Clin Endocrinol Metab. 2000;85: 4168 – 4172. Petryk A, Baker KS, Frohnert B, et al. Blunted response to a growth hormone stimulation test is associated with unfavorable cardiovascular risk factor profile in childhood cancer survivors. Pediatr Blood Cancer. 2013;60:467– 473. Kargi AY, Merriam GR. Testing for growth hormone deficiency in adults: doing without growth hormone-releasing hormone. Curr Opin Endocrinol Diabetes Obes. 2012;19:300 –305. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000;85: 3990 –3993. Forlenza GP, Polgreen LE, Miller BS, MacMillan ML, Wagner JE, Petryk A. Growth hormone treatment of patients with Fanconi anemia after hematopoietic cell transplantation. Pediatr Blood Cancer. 2014;61:1142–1143. Swift M. Fanconi’s anaemia in the genetics of neoplasia. Nature. 1971;230:370 –373. Auerbach AD, Allen RG. Leukemia and preleukemia in Fanconi anemia patients. A review of the literature and report of the International Fanconi Anemia Registry. Cancer Genet Cytogenet. 1991; 51:1–12. Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood. 1994;84: 1650 –1655. Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res. 2007;68(suppl 5):41– 47. Kemp SF, Kuntze J, Attie KM, et al. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab. 2005;90:5247–5253. Quigley CA, Gill AM, Crowe BJ, et al. Safety of growth hormone treatment in pediatric patients with idiopathic short stature. J Clin Endocrinol Metab. 2005;90:5188 –5196. Bowlby DA, Rapaport R. Safety and efficacy of growth hormone therapy in childhood. Pediatr Endocrinol Rev. 2004;2(suppl 1): 68 –77. Harris M, Hofman PL, Cutfield WS. Growth hormone treatment in children: review of safety and efficacy. Paediatr Drugs. 2004;6:93– 106. Gibney J, Johannsson G. Safety of growth hormone replacement therapy in adults. Expert Opin Drug Saf. 2004;3:305–316. Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006;91:3494 –3498. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002;87:3136 –3141. Patterson BC, Chen Y, Sklar CA, et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2014;99:2030 –2037. Pekic S, Popovic V. GH therapy and cancer risk in hypopituitarism: what we know from human studies. Eur J Endocrinol. 2013;169: R89 –R97. Woodmansee WW, Zimmermann AG, Child CJ, et al. Incidence of second neoplasm in childhood cancer survivors treated with GH: an


36.

37.

38.

39.

40.

41. 42.

43.

44.

45.

46.

47.

48.

49.

50.

51.

52.

53.

54.

analysis of GeNeSIS and HypoCCS. Eur J Endocrinol. 2013;168: 565–573. Hartman ML, Xu R, Crowe BJ, et al. Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab. 2013;98:980 –988. Mackenzie S, Craven T, Gattamaneni HR, Swindell R, Shalet SM, Brabant G. Long-term safety of growth hormone replacement after CNS irradiation. J Clin Endocrinol Metab. 2011;96:2756 –2761. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95:167–177. Poidvin A, Touzé E, Ecosse E, et al. Growth hormone treatment for childhood short stature and risk of stroke in early adulthood. Neurology. 2014;83:780 –786. Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012;97:416 – 425. Erfurth EM. Update in mortality in GH-treated patients. J Clin Endocrinol Metab. 2013;98:4219 – 4226. Sävendahl L, Maes M, Albertsson-Wikland K, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012;97:E213–E217. van Bunderen CC, van Varsseveld NC, Erfurth EM, Ket JC, Drent ML. Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity. Clin Endocrinol (Oxf). 2014;81:1–14. Hindmarsh PC, Peters CJ. Growth hormone treatment and stroke: should we be concerned? A case for cohort studies [published online September 10, 2014]. Clin Endocrinol (Oxf). doi: 10.1111/ cen.12611. Malozowski S. Reports of increased mortality and GH: will this affect current clinical practice? J Clin Endocrinol Metab. 2012;97: 380 –383. Cook DM, Rose SR. A review of guidelines for use of growth hormone in pediatric and transition patients. Pituitary. 2012;15:301– 310. Wilson TA, Rose SR, Cohen P, et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr. 2003;143:415– 421. Elder DA, D’Alessio DA, Eyal O, et al. Abnormalities in glucose tolerance are common in children with Fanconi anemia and associated with impaired insulin secretion. Pediatr Blood Cancer. 2008; 51:256 –260. Morrell D, Chase CL, Kupper LL, Swift M. Diabetes mellitus in ataxia-telangiectasia, Fanconi anemia, xeroderma pigmentosum, common variable immune deficiency, and severe combined immune deficiency families. Diabetes. 1986;35:143–147. Polgreen LE, Thomas W, MacMillan ML, Wagner JE, Moran A, Petryk A. First phase insulin release and glucose tolerance in children with Fanconi anemia after hematopoietic cell transplantation. Pediatr Blood Cancer. 2009;53:191–196. Li J, Sipple J, Maynard S, et al. Fanconi anemia links reactive oxygen species to insulin resistance and obesity. Antioxid Redox Signal. 2012;17:1083–1098. Pagano G, Youssoufian H. Fanconi anaemia proteins: major roles in cell protection against oxidative damage. BioEssays. 2003;25:589 – 595. Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med. 1996;20:463– 466. Sigfrid LA, Cunningham JM, Beeharry N, et al. Antioxidant enzyme activity and mRNA expression in the islets of Langerhans from the


doi: 10.1210/jc.2014-4357

55.

56.

57.

58.

59.

60.

61.

62. 63.

64.

65.

66.

67.

68. 69.

70.

BB/S rat model of type 1 diabetes and an insulin-producing cell line. J Mol Med (Berl). 2004;82:325–335. Eyal O, Blum S, Mueller R, Smith FO, Rose SR. Improved growth velocity during thyroid hormone therapy in children with Fanconi anemia and borderline thyroid function. Pediatr Blood Cancer. 2008;51:652– 656. Rose SR, Lustig RH, Pitukcheewanont P, et al. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab. 1999;84:4472– 4479. Rose SR. Improved diagnosis of mild hypothyroidism using timeof-day normal ranges for thyrotropin. J Pediatr. 2010;157:662– 667; 667.e1. Sherafat-Kazemzadeh R, Mehta SN, Care MM, Kim MO, Williams DA, Rose SR. Small pituitary size in children with Fanconi anemia. Pediatr Blood Cancer. 2007;49:166 –170. Trivin C, Gluckman E, Leblanc T, Cousin MN, Soulier J, Brauner R. Factors and markers of growth hormone secretion and gonadal function in Fanconi anemia. Growth Horm IGF Res. 2007;17:122– 129. Lamine F, Turki Z, Mrad R, et al. Growth hormone deficiency and pituitary stalk interruption in Fanconi anemia [in French]. Ann Endocrinol (Paris). 2008;69:63– 68. Massa GG, Heinrichs C, Vamos E, Van Vliet G. Hypergonadotropic hypogonadism in a boy with Fanconi anemia with growth hormone deficiency and pituitary stalk interruption. J Pediatr. 2002;140:277. Alter BP, Frissora CL, Halpérin DS, et al. Fanconi’s anaemia and pregnancy. Br J Haematol. 1991;77:410 – 418. Nabhan SK, Bitencourt MA, Duval M, et al. Fertility recovery and pregnancy after allogeneic hematopoietic stem cell transplantation in Fanconi anemia patients. Haematologica. 2010;95:1783–1787. Larder R, Chang L, Clinton M, Brown P. Gonadotropin-releasing hormone regulates expression of the DNA damage repair gene, Fanconi anemia A, in pituitary gonadotroph cells. Biol Reprod. 2004; 71:828 – 836. Cheng NC, van de Vrugt HJ, van der Valk MA, et al. Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum Mol Genet. 2000;9:1805–1811. Nadler JJ, Braun RE. Fanconi anemia complementation group C is required for proliferation of murine primordial germ cells. Genesis. 2000;27:117–123. Sklavos MM, Giri N, Stratton P, Alter BP, Pinto LA. Anti-Müllerian hormone deficiency in females with Fanconi anemia. J Clin Endocrinol Metab. 2014;99:1608 –1614. Stewart J, Turner KJ. Inhibin B as a potential biomarker of testicular toxicity. Cancer Biomark. 2005;1:75–91. Yanovski JA, Rose SR, Municchi G, et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med. 2003;348:908 –917. Rose SR, Rutter MM, Mueller R, et al. Bone mineral density is normal in children with Fanconi anemia. Pediatr Blood Cancer. 2011;57:1034 –1038.


811

71. Petryk A, Polgreen LE, Barnum JL, Zhang L, Hodges JS, Baker KS, Wagner JE, Steinberger J, MacMillan ML. Bone mineral density in children with Fanconi anemia after hematopoietic cell transplantation [published online January 12, 2015]. Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2015.01.002. 72. Zemel BS, Leonard MB, Kelly A, et al. Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab. 2010;95:1265– 1273. 73. Polgreen LE, Rudser K, Deyo M, Smith A, Baker KS, Petryk A. Changes in biomarkers of bone resorption over the first six months after pediatric hematopoietic cell transplantation. Pediatr Transplant. 2012;16:852– 857. 74. Petryk A, Bergemann TL, Polga KM, et al. Prospective study of changes in bone mineral density and turnover in children after hematopoietic cell transplantation. J Clin Endocrinol Metab. 2006; 91:899 –905. 75. Pulsipher MA, Skinner R, McDonald GB, et al. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines. Biol Blood Marrow Transplant. 2012;18:334 –347. 76. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–58. 77. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011; 96:1911–1930. 78. Grigg AP, Shuttleworth P, Reynolds J, et al. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2006;91:3835–3843. 79. Kananen K, Volin L, Laitinen K, Alfthan H, Ruutu T, Välimäki MJ. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab. 2005;90:3877–3885. 80. Ward L, Tricco AC, Phuong P, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev. 2007;4:CD005324. 81. Baim S, Leonard MB, Bianchi ML, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom. 2008;11:6 –21. 82. Gordon CM, Bachrach LK, Carpenter TO, et al. Dual energy x-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom. 2008;11:43–58. 83. Ward LM, Petryk A, Gordon CM. Use of bisphosphonates in the treatment of pediatric osteoporosis. Int J Clin Rheumatol. 2009;4: 657– 672.


Fanconi anemia in blacks.

Improving survival for Fanconi anemia patients.

Genetic counseling for Fanconi anemia: crosslinking disciplines.

Classical Fanconi anemia in a family with hypoplastic anemia.

Fanconi anemia proteins in telomere maintenance.

Alteration of a nuclease in Fanconi anemia.

Fanconi anemia in black African children.

SnapShot: Fanconi anemia and associated proteins.

Screening for craniomandibular disorders in orthodontic treatment.

Dysregulated Ca2+ homeostasis in Fanconi anemia cells.

Leukemia and preleukemia in Fanconi anemia patients. A review of the literature and report of the International Fanconi Anemia Registry.

Fanconi anemia founder mutation in Macedonian patients.

The diagnosis of and treatment recommendations for anxiety disorders.

Programmable bio-nanochip-based cytologic testing of oral potentially malignant disorders in Fanconi anemia.

Allosteric Targeting of the Fanconi Anemia Ubiquitin-Conjugating Enzyme Ube2T by Fragment Screening.

Diagnosis of Fanconi anemia by diepoxybutane analysis.

The maternal side of Fanconi Anemia.

Fanconi anemia pathway defects in inherited and sporadic cancers.

Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer Therapy.

Fanconi anemia: evidence for linkage heterogeneity on chromosome 20q.

[Fanconi anemia: report of a new case].

Oral lesions associated with Fanconi anemia.

Alternative donor hematopoietic cell transplantation for Fanconi anemia.

What is wrong with Fanconi anemia cells?